SEARCH

SEARCH BY CITATION

References

  • 1
    Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109: 251-256.
  • 2
    Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol 2004;113: 11291136.
  • 3
    Valenta R, Kraft D. From allergen structure to new forms of allergen-specific immunotherapy. Curr Opin Immunol 2002;14: 718727.
  • 4
    Kagi MK, Wuthrich B. Different methods of local allergen-specific immunotherapy. Allergy 2002;57: 379388.
  • 5
    Jarolim E, Rumpold H, Endler AT, Ebner H, Breitenbach M, Scheiner O et al. IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa. Allergy 1989;44: 385395.
  • 6
    Swoboda I, Jilek A, Ferreira F, Engel E, Hoffmann-Sommergruber K, Scheiner O et al. Isoforms of Bet v 1, the major birch pollen allergen, analyzed by liquid chromatography, mass spectrometry, and cDNA cloning. J Biol Chem 1995;270: 26072613.
  • 7
    Ferreira F, Hirtenlehner K, Jilek A, Godnik-Cvar J, Breiteneder H, Grimm R et al. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 1996;183: 599609.
  • 8
    Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997;99: 16731681.
  • 9
    Pauli G, Purohit A, Oster JP, De Blay F, Vrtala S, Niederberger V et al. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin Exp Allergy 2000;30: 10761084.
  • 10
    Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004;101(Suppl. 2):1467714682.
  • 11
    Wiedermann U, Jahn-Schmid B, Bohle B, Repa A, Renz H, Kraft D et al. Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant bet v 1, the major birch pollen allergen, in a murine model of type I allergy. J Allergy Clin Immunol 1999;103: 12021210.
  • 12
    Winkler B, Baier K, Wagner S, Repa A, Eichler HG, Scheiner O et al. Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. Clin Exp Allergy 2002;32: 3036.
  • 13
    Wiedermann U, Herz U, Baier K, Vrtala S, Neuhaus-Steinmetz U, Bohle B et al. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice. Int Arch Allergy Immunol 2001;126: 6877.
  • 14
    Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998;28: 914925.
  • 15
    Astori M, von Garnier C, Kettner A, Dufour N, Corradin G, Spertini F. Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. J Immunol 2000;165: 34973505.
  • 16
    O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004;10: 801805.
  • 17
    Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389: 737742.
  • 18
    Alard P, Clark SL, Kosiewicz MM. Mechanisms of tolerance induced by TGF beta-treated APC: CD4 regulatory T cells prevent the induction of the immune response possibly through a mechanism involving TGF beta. Eur J Immunol 2004;34: 10211030.
  • 19
    Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A 1992;89: 421425.
  • 20
    McMenamin C, McKersey M, Kuhnlein P, Hunig T, Holt PG. Gamma delta T cells down-regulate primary IgE responses in rats to inhaled soluble protein antigens. J Immunol 1995;154: 43904394.
  • 21
    Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182: 1832.
  • 22
    Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4: 330336.
  • 23
    Hufnagl K, Winkler B, Focke M, Valenta R, Scheiner O, Renz H et al. Intranasal tolerance induction with polypeptides derived from three non cross-reactive major aeroallergens prevents allergic poly-sensitization in mice. J Allergy Clin Immunol 2005;116: 370376.
  • 24
    Winkler B, Bolwig C, Seppala U, Spangfort MD, Ebner C, Wiedermann U. Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy. Immunology 2003;110: 376385.
  • 25
    Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198: 18751886.
  • 26
    Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299: 10571061.
  • 27
    Chung Y, Chang SY, Kang CY. Kinetic analysis of oral tolerance: memory lymphocytes are refractory to oral tolerance. J Immunol 1999;163: 36923698.
  • 28
    Leishman AJ, Garside P, Mowat AM. Induction of oral tolerance in the primed immune system: influence of antigen persistence and adjuvant form. Cell Immunol 2000;202: 7178.
  • 29
    Foussat A, Cottrez F, Brun V, Fournier N, Breittmayer JP, Groux H. A comparative study between T regulatory type 1 and CD4+CD25+ T cells in the control of inflammation. J Immunol 2003;171: 50185026.
  • 30
    Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001;2: 725731.
  • 31
    Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002;195: 603616.
  • 32
    Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002;195: 16411646.
  • 33
    Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001;2: 816822.
  • 34
    Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 2004;172: 52135221.
  • 35
    van Nierop K, de Groot C. Human follicular dendritic cells: function, origin and development. Semin Immunol 2002;14: 251.
  • 36
    Kosco-Vilbois MH. Are follicular dendritic cells really good for nothing? Nat Rev Immunol 2003;3: 764769.